Tracie L. Miner
Washington University in St. Louis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tracie L. Miner.
Nature | 2008
Li Ding; Gad Getz; David A. Wheeler; Elaine R. Mardis; Michael D. McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M. Muzny; Margaret Morgan; Lucinda Fulton; Robert S. Fulton; Qunyuan Zhang; Michael C. Wendl; Michael S. Lawrence; David E. Larson; Ken Chen; David J. Dooling; Aniko Sabo; Alicia Hawes; Hua Shen; Shalini N. Jhangiani; Lora Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E. Scherer; Kerstin Clerc
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers—including NF1, APC, RB1 and ATM—and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Nature | 2005
Tarjei S. Mikkelsen; LaDeana W. Hillier; Evan E. Eichler; Michael C. Zody; David B. Jaffe; Shiaw-Pyng Yang; Wolfgang Enard; Ines Hellmann; Kerstin Lindblad-Toh; Tasha K. Altheide; Nicoletta Archidiacono; Peer Bork; Jonathan Butler; Jean L. Chang; Ze Cheng; Asif T. Chinwalla; Pieter J. de Jong; Kimberley D. Delehaunty; Catrina C. Fronick; Lucinda L. Fulton; Yoav Gilad; Gustavo Glusman; Sante Gnerre; Tina Graves; Toshiyuki Hayakawa; Karen E. Hayden; Xiaoqiu Huang; Hongkai Ji; W. James Kent; Mary Claire King
Here we present a draft genome sequence of the common chimpanzee (Pan troglodytes). Through comparison with the human genome, we have generated a largely complete catalogue of the genetic differences that have accumulated since the human and chimpanzee species diverged from our common ancestor, constituting approximately thirty-five million single-nucleotide changes, five million insertion/deletion events, and various chromosomal rearrangements. We use this catalogue to explore the magnitude and regional variation of mutational forces shaping these two genomes, and the strength of positive and negative selection acting on their genes. In particular, we find that the patterns of evolution in human and chimpanzee protein-coding genes are highly correlated and dominated by the fixation of neutral and slightly deleterious alleles. We also use the chimpanzee genome as an outgroup to investigate human population genetics and identify signatures of selective sweeps in recent human evolution.Here we present a draft genome sequence of the common chimpanzee (Pan troglodytes). Through comparison with the human genome, we have generated a largely complete catalogue of the genetic differences that have accumulated since the human and chimpanzee species diverged from our common ancestor, constituting approximately thirty-five million single-nucleotide changes, five million insertion/deletion events, and various chromosomal rearrangements. We use this catalogue to explore the magnitude and regional variation of mutational forces shaping these two genomes, and the strength of positive and negative selection acting on their genes. In particular, we find that the patterns of evolution in human and chimpanzee protein-coding genes are highly correlated and dominated by the fixation of neutral and slightly deleterious alleles. We also use the chimpanzee genome as an outgroup to investigate human population genetics and identify signatures of selective sweeps in recent human evolution.
Nature | 2003
Helen Skaletsky; Tomoko Kuroda-Kawaguchi; Patrick Minx; Holland S. Cordum; LaDeana W. Hillier; Laura G. Brown; Sjoerd Repping; Johar Ali; Tamberlyn Bieri; Asif T. Chinwalla; Andrew Delehaunty; Kim D. Delehaunty; Hui Du; Ginger Fewell; Lucinda Fulton; Robert S. Fulton; Tina Graves; Shunfang Hou; Philip Latrielle; Shawn Leonard; Elaine R. Mardis; Rachel Maupin; John D. McPherson; Tracie L. Miner; William E. Nash; Christine Nguyen; Philip Ozersky; Kymberlie H. Pepin; Susan Rock; Tracy Rohlfing
The male-specific region of the Y chromosome, the MSY, differentiates the sexes and comprises 95% of the chromosomes length. Here, we report that the MSY is a mosaic of heterochromatic sequences and three classes of euchromatic sequences: X-transposed, X-degenerate and ampliconic. These classes contain all 156 known transcription units, which include 78 protein-coding genes that collectively encode 27 distinct proteins. The X-transposed sequences exhibit 99% identity to the X chromosome. The X-degenerate sequences are remnants of ancient autosomes from which the modern X and Y chromosomes evolved. The ampliconic class includes large regions (about 30% of the MSY euchromatin) where sequence pairs show greater than 99.9% identity, which is maintained by frequent gene conversion (non-reciprocal transfer). The most prominent features here are eight massive palindromes, at least six of which contain testis genes.
Nature | 2008
Timothy J. Ley; Elaine R. Mardis; Li Ding; Bob Fulton; Michael D. McLellan; Ken Chen; David J. Dooling; Brian H. Dunford-Shore; Sean McGrath; Matthew Hickenbotham; Lisa Cook; Rachel Abbott; David E. Larson; Dan Koboldt; Craig S. Pohl; Scott M. Smith; Amy Hawkins; Scott Abbott; Devin P. Locke; LaDeana W. Hillier; Tracie L. Miner; Lucinda Fulton; Vincent Magrini; Todd Wylie; Jarret Glasscock; Joshua J. Conyers; Nathan Sander; Xiaoqi Shi; John R. Osborne; Patrick Minx
Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about 13,000 adults in the United States each year. The treatment of this disease has changed little in the past two decades, because most of the genetic events that initiate the disease remain undiscovered. Whole-genome sequencing is now possible at a reasonable cost and timeframe to use this approach for the unbiased discovery of tumour-specific somatic mutations that alter the protein-coding genes. Here we present the results obtained from sequencing a typical acute myeloid leukaemia genome, and its matched normal counterpart obtained from the same patient’s skin. We discovered ten genes with acquired mutations; two were previously described mutations that are thought to contribute to tumour progression, and eight were new mutations present in virtually all tumour cells at presentation and relapse, the function of which is not yet known. Our study establishes whole-genome sequencing as an unbiased method for discovering cancer-initiating mutations in previously unidentified genes that may respond to targeted therapies.
PLOS Biology | 2003
Lincoln Stein; Zhirong Bao; Darin Blasiar; Thomas Blumenthal; Michael R. Brent; Nansheng Chen; Asif T. Chinwalla; Laura Clarke; Chris Clee; Avril Coghlan; Alan Coulson; Peter D'Eustachio; David H. A. Fitch; Lucinda A. Fulton; Robert Fulton; Sam Griffiths-Jones; Todd W. Harris; LaDeana W. Hillier; Ravi S. Kamath; Patricia E. Kuwabara; Elaine R. Mardis; Marco A. Marra; Tracie L. Miner; Patrick Minx; James C. Mullikin; Robert W. Plumb; Jane Rogers; Jacqueline E. Schein; Marc Sohrmann; John Spieth
The soil nematodes Caenorhabditis briggsae and Caenorhabditis elegans diverged from a common ancestor roughly 100 million years ago and yet are almost indistinguishable by eye. They have the same chromosome number and genome sizes, and they occupy the same ecological niche. To explore the basis for this striking conservation of structure and function, we have sequenced the C. briggsae genome to a high-quality draft stage and compared it to the finished C. elegans sequence. We predict approximately 19,500 protein-coding genes in the C. briggsae genome, roughly the same as in C. elegans. Of these, 12,200 have clear C. elegans orthologs, a further 6,500 have one or more clearly detectable C. elegans homologs, and approximately 800 C. briggsae genes have no detectable matches in C. elegans. Almost all of the noncoding RNAs (ncRNAs) known are shared between the two species. The two genomes exhibit extensive colinearity, and the rate of divergence appears to be higher in the chromosomal arms than in the centers. Operons, a distinctive feature of C. elegans, are highly conserved in C. briggsae, with the arrangement of genes being preserved in 96% of cases. The difference in size between the C. briggsae (estimated at approximately 104 Mbp) and C. elegans (100.3 Mbp) genomes is almost entirely due to repetitive sequence, which accounts for 22.4% of the C. briggsae genome in contrast to 16.5% of the C. elegans genome. Few, if any, repeat families are shared, suggesting that most were acquired after the two species diverged or are undergoing rapid evolution. Coclustering the C. elegans and C. briggsae proteins reveals 2,169 protein families of two or more members. Most of these are shared between the two species, but some appear to be expanding or contracting, and there seem to be as many as several hundred novel C. briggsae gene families. The C. briggsae draft sequence will greatly improve the annotation of the C. elegans genome. Based on similarity to C. briggsae, we found strong evidence for 1,300 new C. elegans genes. In addition, comparisons of the two genomes will help to understand the evolutionary forces that mold nematode genomes.
Nature Genetics | 2004
Michael McClelland; Kenneth E. Sanderson; Sandra W. Clifton; Phil Latreille; Steffen Porwollik; Aniko Sabo; Rekha Meyer; Tamberlyn Bieri; Phil Ozersky; Michael D. McLellan; C Richard Harkins; Chunyan Wang; Christine Nguyen; Amy Berghoff; Glendoria Elliott; Sara Kohlberg; Cindy Strong; Feiyu Du; Jason Carter; Colin Kremizki; Dan Layman; Shawn Leonard; Hui Sun; Lucinda Fulton; William E. Nash; Tracie L. Miner; Patrick Minx; Kim D. Delehaunty; Catrina C. Fronick; Vincent Magrini
Salmonella enterica serovars often have a broad host range, and some cause both gastrointestinal and systemic disease. But the serovars Paratyphi A and Typhi are restricted to humans and cause only systemic disease. It has been estimated that Typhi arose in the last few thousand years. The sequence and microarray analysis of the Paratyphi A genome indicates that it is similar to the Typhi genome but suggests that it has a more recent evolutionary origin. Both genomes have independently accumulated many pseudogenes among their ∼4,400 protein coding sequences: 173 in Paratyphi A and ∼210 in Typhi. The recent convergence of these two similar genomes on a similar phenotype is subtly reflected in their genotypes: only 30 genes are degraded in both serovars. Nevertheless, these 30 genes include three known to be important in gastroenteritis, which does not occur in these serovars, and four for Salmonella-translocated effectors, which are normally secreted into host cells to subvert host functions. Loss of function also occurs by mutation in different genes in the same pathway (e.g., in chemotaxis and in the production of fimbriae).
Journal of Medical Genetics | 2008
David A. Koolen; Andrew J. Sharp; Jane Hurst; Helen V. Firth; Samantha J. L. Knight; A. Goldenberg; P. Saugier-Veber; Rolph Pfundt; Lisenka E.L.M. Vissers; A Destree; Bernard Grisart; Liesbeth Rooms; N. Van der Aa; Michael Field; Anna Hackett; Kathleen Bell; Małgorzata J.M. Nowaczyk; Grazia M. Mancini; Pino J. Poddighe; Charles E. Schwartz; E. Rossi; M. De Gregori; L. L. Antonacci-Fulton; Michael D. McLellan; J. M. Garrett; M. A. Wiechert; Tracie L. Miner; S. Crosby; Roberto Ciccone; Lionel Willatt
Background: The chromosome 17q21.31 microdeletion syndrome is a novel genomic disorder that has originally been identified using high resolution genome analyses in patients with unexplained mental retardation. Aim: We report the molecular and/or clinical characterisation of 22 individuals with the 17q21.31 microdeletion syndrome. Results: We estimate the prevalence of the syndrome to be 1 in 16 000 and show that it is highly underdiagnosed. Extensive clinical examination reveals that developmental delay, hypotonia, facial dysmorphisms including a long face, a tubular or pear-shaped nose and a bulbous nasal tip, and a friendly/amiable behaviour are the most characteristic features. Other clinically important features include epilepsy, heart defects and kidney/urologic anomalies. Using high resolution oligonucleotide arrays we narrow the 17q21.31 critical region to a 424 kb genomic segment (chr17: 41046729–41470954, hg17) encompassing at least six genes, among which is the gene encoding microtubule associated protein tau (MAPT). Mutation screening of MAPT in 122 individuals with a phenotype suggestive of 17q21.31 deletion carriers, but who do not carry the recurrent deletion, failed to identify any disease associated variants. In five deletion carriers we identify a <500 bp rearrangement hotspot at the proximal breakpoint contained within an L2 LINE motif and show that in every case examined the parent originating the deletion carries a common 900 kb 17q21.31 inversion polymorphism, indicating that this inversion is a necessary factor for deletion to occur (p<10−5). Conclusion: Our data establish the 17q21.31 microdeletion syndrome as a clinically and molecularly well recognisable genomic disorder.
PLOS ONE | 2007
Jenifer L. Marks; Michael D. McLellan; Maureen F. Zakowski; Alex E. Lash; Yumi Kasai; Stephen Broderick; Inderpal S. Sarkaria; DuyKhanh Pham; Bhuvanesh Singh; Tracie L. Miner; Ginger Fewell; Lucinda Fulton; Elaine R. Mardis; Richard Wilson; Mark G. Kris; Valerie W. Rusch; Harold E. Varmus; William Pao
Background Fifty percent of lung adenocarcinomas harbor somatic mutations in six genes that encode proteins in the EGFR signaling pathway, i.e., EGFR, HER2/ERBB2, HER4/ERBB4, PIK3CA, BRAF, and KRAS. We performed mutational profiling of a large cohort of lung adenocarcinomas to uncover other potential somatic mutations in genes of this signaling pathway that could contribute to lung tumorigenesis. Methodology/Principal Findings We analyzed genomic DNA from a total of 261 resected, clinically annotated non-small cell lung cancer (NSCLC) specimens. The coding sequences of 39 genes were screened for somatic mutations via high-throughput dideoxynucleotide sequencing of PCR-amplified gene products. Mutations were considered to be somatic only if they were found in an independent tumor-derived PCR product but not in matched normal tissue. Sequencing of 9MB of tumor sequence identified 239 putative genetic variants. We further examined 22 variants found in RAS family genes and 135 variants localized to exons encoding the kinase domain of respective proteins. We identified a total of 37 non-synonymous somatic mutations; 36 were found collectively in EGFR, KRAS, BRAF, and PIK3CA. One somatic mutation was a previously unreported mutation in the kinase domain (exon 16) of FGFR4 (Glu681Lys), identified in 1 of 158 tumors. The FGFR4 mutation is analogous to a reported tumor-specific somatic mutation in ERBB2 and is located in the same exon as a previously reported kinase domain mutation in FGFR4 (Pro712Thr) in a lung adenocarcinoma cell line. Conclusions/Significance This study is one of the first comprehensive mutational analyses of major genes in a specific signaling pathway in a sizeable cohort of lung adenocarcinomas. Our results suggest the majority of gain-of-function mutations within kinase genes in the EGFR signaling pathway have already been identified. Our findings also implicate FGFR4 in the pathogenesis of a subset of lung adenocarcinomas.
Genome Research | 2001
Paul F. Cliften; LaDeana W. Hillier; Lucinda Fulton; Tina Graves; Tracie L. Miner; Warren Gish; Robert H. Waterston; Mark Johnston
Blood | 2008
Michael H. Tomasson; Zhifu Xiang; Richard Walgren; Yu Zhao; Yumi Kasai; Tracie L. Miner; Rhonda E. Ries; Olga Y. Lubman; Daved H. Fremont; Michael D. McLellan; Jacqueline E. Payton; Peter Westervelt; John F. DiPersio; Daniel C. Link; Matthew J. Walter; Timothy A. Graubert; Mark A. Watson; Jack Baty; Sharon Heath; William D. Shannon; Rakesh Nagarajan; Clara D. Bloomfield; Elaine R. Mardis; Richard Wilson; Timothy J. Ley